BETAAccess all features while we're in beta! Some features may become paid later.Send feedback →
vpside

TKNO

Alpha Teknova, Inc.
Nasdaq · In vitro & in vivo diagnostic substances (SIC 2835) · FY ends 31 Dec

Revenue, quarterly

$12M+18.5% year on year
$15M$10M$5M$0
Q3 ’21Q4 ’22Q1 ’24Q1 ’25Q2 ’26
Company filings · 10-Q filed 6 Aug 2026 · Q4 = FY − 9Mvpside.com

Gross margin, trailing twelve months

34.6%+10.9 pp year on year
50%40%30%20%10%
Q2 ’22Q2 ’23Q2 ’24Q2 ’25Q2 ’26
Company filings · 10-Q filed 6 Aug 2026 · TTM = last four quartersvpside.com

Cash and cash equivalents, quarter-end

$6M+83.3% year on year
$100M$50M$0
Q3 ’21Q4 ’22Q1 ’24Q1 ’25Q2 ’26
Company filings · 10-Q filed 6 Aug 2026 · balance sheet, period-endvpside.com

Free cash flow, trailing twelve months

−$7M
$20M$0−$20M−$40M−$60M
Q3 ’22Q3 ’23Q3 ’24Q2 ’25Q2 ’26
Company filings · 10-Q filed 6 Aug 2026 · TTM = last four quartersvpside.com
Chart 05 is empty
Chart 06 is empty